GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fulcrum Therapeutics Inc (NAS:FULC) » Definitions » Net Income (Continuing Operations)

FULC (Fulcrum Therapeutics) Net Income (Continuing Operations) : $-0.51 Mil (TTM As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Fulcrum Therapeutics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Fulcrum Therapeutics's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was $-17.66 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.51 Mil.

Fulcrum Therapeutics Net Income (Continuing Operations) Historical Data

The historical data trend for Fulcrum Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulcrum Therapeutics Net Income (Continuing Operations) Chart

Fulcrum Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Continuing Operations)
Get a 7-Day Free Trial -70.82 -80.85 -109.87 -97.34 -9.73

Fulcrum Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.87 55.41 -21.70 -16.57 -17.66

Fulcrum Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulcrum Therapeutics  (NAS:FULC) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Fulcrum Therapeutics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Fulcrum Therapeutics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulcrum Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fulcrum Therapeutics Inc (NAS:FULC) » Definitions » Net Income (Continuing Operations)
Comparable Companies
ERAS OLMA CTMX PRTA ABSI RIGL BNTC ATYR RZLT ARCT VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
26 Landsdowne Street, Cambridge, MA, USA, 02139
Website
https://www.fulcrumtx.com
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Executives
Greg Tourangeau officer: Controller C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alex Sapir director, officer: See Remarks C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alan A Musso officer: Chief Financial Officer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J Gould director, officer: President & CEO C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Santiago Arroyo officer: Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Hayes Melvin H. Iii officer: Chief Operating Officer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Esther Rajavelu officer: Chief Financial Officer 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sonja Banks director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bryan Stuart officer: Chief Operating Officer C/O CIVITAS THERAPEUTICS, INC., 190 EVERETT AVENUE, CHELSEA MA 02150
Christopher Moxham officer: Chief Scientific Officer 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Peter G. Thomson officer: VP Finance & Accounting C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139